Scientific Opinion on the safety of astaxanthin-rich ingredients (AstaREAL A1010 and AstaREAL L10) as novel food ingredients

EFSA Journal

Volumn 12, Issue 7, 2014, Pages

[No Author Info available]

Author keywords

astaxanthin; Haematococcus pluvialis; ingredient; novel food

Indexed keywords

EID: 85029009354     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2014.3757     Document Type: Article

References (88)

1. Arora A, Willhite CA and Liebler DC, 2001. Interactions of β-carotene and cigarette smoke in human bronchial epithelial cell. Carcinogenesis, 22, 1173–1178.
2. Becker W and Pearson M, 2002. Riksmaten 1997–98. Kostvanor och näringsintag i Sverige. Metod-och resultatanalys. Livsmedelsverket, 199 pp.
3. Beutner S, Bloedorn B, Frixel S, Böanco IH, Hoffmann T, Martin H-D, Mayer B, Noack P, Ruck C, Schmidt M, Schülke I, Sell S, Ernst H, Haremza S, Seybold G, Sies H, Stahl W and Walsh R, 2001. Quantitative assessment of antioxidant properties of natural colorants and phytochemicals: carotenoids, flavonoids, phenols and indigoids. The role of β-carotene in antioxidant functions. Journal of the Science of Food and Agriculture, 81, 559–568.
4. BioReal (Sweden) AB, 2011, unpublished. Blood plasma carotenoid composition in a double blind randomised study to evaluate the effect of astaxanthin supplementation in healthy men attending Vasaloppet 2005. Summary. 1 pp.
5. Borody TJ, 1999, unpublished. The safety, tolerability and efficacy of the antioxidant astaxanthin in the treatment of Helicobacter pylori infection. Final Report GS98/C01. Centre for Digestive Diseases, ACHS Accredited Day Procedure Centre, Five Dock, Australia, 6 pp.
6. Chew BP, Park JS, Wong MW and Wong TS, 1999. A comparison of the anticancer activities of dietary beta-carotene, canthaxanthin and astaxanthin in mice in vivo. Anticancer Research, 19, 1849–1853.
7. Choi HD, Kang HE, Yang SH, Lee MG and Shin WG, 2011. Pharmacokinetics and first-pass metabolism of astaxanthin in rats. British Journal of Nutrition, 105, 220–227.
8. Clark RM, Yao L, She L and Furr HC, 1998. A comparison of lycopene and canthaxanthin absorption: using the rat to study the absorption of non-provitamin A carotenoids. Lipids, 33, 159–163.
9. Clark RM, Yao L, She L and Furr HC, 2000. A comparison of lycopene and astaxanthin absorption from corn oil and olive oil emulsions. Lipids, 35, 803–806.
10. Coral-Hinostroza GN, Ytrestoyl T, Ruyter B and Bjerkeng B, 2004. Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3′R/S isomers of astaxanthin fatty acyl diesters. Comparative Biochemistry and Physiology. Toxicology and Pharmacology, 139, 99–110.
11. de Pee S, West CE, Hautvast JGAJ, Muhilal, Karyadi D and West CE, 1995. Lack of improvement in vitamin A status with increased consumption of dark-green leafy vegetables. The Lancet, 346, 75–81.
12. Edwards CN, 1998, unpublished-a. Haematococcus pluvialis, Ames test “treat and plate” test. Report 28708. Scantox, Skensved, Denmark, 20 pp.
13. Edwards CN, 1998, unpublished-b. Haematococcus pluvialis, mouse micronucleus test. Report 28832. Scantox, Skensved, Denmark, 15 pp.
14. Edwards CN, 1998, unpublished-c. Haematococcus pluvialis, in vitro mammalian cell gene mutation test performed with mouse lymphoma cells (L5178Y). Report 28709. Scantox, Skensved, Denmark, 20 pp.
15. EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) on the request from the European Commission on the safety of use of colouring agents in animal nutrition. PART I. General Principles and Astaxanthin. The EFSA Journal 2005, 291, 1–40.
16. EFSA (European Food Safety Authority), 2006. Opinion of the Scientific Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) on the safety and efficacy of the product AQUASTA, an Astaxanthin-rich Phaffia rhodozyma ATCC SD-5340 for salmon and trout. The EFSA Journal 2006, 320, 1–19.
17. EFSA (European Food Safety Authority), 2007a. Scientific Opinion of the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) on the safety and efficacy of CAROPHYLL® Stay-Pink (astaxanthin dimethyldisuccinate) as feed additive for salmon and trout. The EFSA Journal 2007, 574, 1–25.
18. EFSA (European Food Safety Authority), 2007b. Scientific Opinion of the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) on a request from the European Commission on safety and efficacy of Panaferd-AX (red carotenoid-rich bacterium Paracoccus carotinifaciens) as feed additive for salmon and trout. The EFSA Journal 2007, 546, 1–30.
19. EFSA (European Food Safety Authority), 2011. Guidance of EFSA. Use of the EFSA Comprehensive European Food Consumption Database in exposure assessment. EFSA Journal 2011;9(3):2097, 34 pp. doi:10.2903/j.efsa.2011.2097
20. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2014a. Scientific Opinion on the safety and efficacy of astaxanthin (CAROPHYLL® Pink 10% CWS) for salmonids and ornamental fish. EFSA Journal 2014;12(6):3725, 33 pp. doi:10.2903/j.efsa.2014.3725
21. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2014b. Scientific Opinion on the safety and efficacy of synthetic astaxanthin as feed additive for salmon and trout, other fish, ornamental fish, crustaceans and ornamental birds. EFSA Journal 2014;12(6):3724, 35 pp. doi:10.2903/j.efsa.2014.3724
22. EFSA SC (Scientific Committee), 2012. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579, 32 pp. doi:10.2903/j.efsa.2012.2579
23. Eroglu A, Hruszkewycz DP, Curley RW, Jr. and Harrison EH, 2010. The eccentric cleavage product of beta-carotene, beta-apo-13-carotenone, functions as an antagonist of RXRalpha. Archives of Biochemistry and Biophysics, 504, 11–16.
24. Ershov Iu V, Dmitrovskii AA and Bykhovskii V, 1993. [The character of the interaction of beta-carotene-15, 15′-dioxygenase from rabbit small intestine with lycopene, 15,15′-dehydro-beta-carotene, lutein, and astaxanthine]. Biokhimiia, 58, 733–739.
25. Fawell JK, Mitchell RE, Everett DJ and Hill RE, 1999. The toxicity of cyanobacterial toxins in the mouse: I microcystin-LR. Human and Experimental Toxicology, 18, 162–167.
26. Gillio Tos E, Maraschin R, Orlando L, Zaninelli P and Piccioli B, 1995, unpublished. Haematococcus pluvialis, unicellular green algae: acute toxicity study in rats treated by oral route. RBM Report 950053. Instituto di Recerche Biomediche “Antoine Marxer” (RBM), Colleretto Giacosa, Torino, Italy, 21 pp.
27. Gilroy DJ, Kauffman KW, Hall RA, Huang X and Chu FS, 2000. Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. Environmental Health Perspectives, 108, 435–439.
28. Gradelet S, Leclerc J, Siess MH and Astorg PO, 1996a. beta-Apo-8'-carotenal, but not beta-carotene, is a strong inducer of liver cytochromes P4501A1 and 1A2 in rat. Xenobiotica, 26, 909–919.
29. Gradelet S, Astorg P, Leclerc J, Chevalier J, Vernevaut M-F and Siess M-H, 1996b. Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobiotica, 26, 49–63.
30. Hartmann D, Thurmann PA, Spitzer V, Schalch W, Manner B and Cohn W, 2004. Plasma kinetics of zeaxanthin and 3′-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. American Journal of Clinical Nutrition, 79, 410–417.
31. Hedman CJ, Krick WR, Karner Perkins DA, Harrahy EA and Sonzogni WC, 2008. New measurements of cyanobacterial toxins in natural waters using high performance liquid chromatography coupled to tandem mass spectrometry. Journal of Environmental Quality, 37, 1817–1824.
32. Hoare J, Henderson L, Bates CJ, Prentice A, Birch M, Swan G and Farron M, 2004. The national diet & nutrition survey: adults aged 19 to 64 years. Summary report. Volume 5, 142 pp.
33. JECFA, 1996. Canthaxanthin. In: Toxicological evaluation of certain food additives and contaminants in food. WHO Food Additive Series No 35, 1996. World Health Organization, Geneva.
34. Jewell C and O'Brien NM, 1999. Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat. British Journal of Nutrition, 81, 235–242.
35. Karppi J, Rissanen TH, Nyyssonen K, Kaikkonen J, Olsson AG, Voutilainen S and Salonen JT, 2007. Effects of astaxanthin supplementation on lipid peroxidation. International Journal for Vitamin and Nutrition Research, 77, 3–11.
36. Kim JH, Chang MJ, Choi HD, Youn YK, Kim JT, Oh JM and Shin WG, 2011. Protective effects of Haematococcus astaxanthin on oxidative stress in healthy smokers. Journal of Medicinal Food, 14, 1469–1475.
37. Kistler A, Liechti H, Pichard L, Wolz E, Oesterhelt G, Hayes A and Maurel P, 2002. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Archives of Toxicology, 75, 665–675.
38. Kupcinskas L, Lafolie P, Wadstrom T, Kludelis G, Jonaitas L and Adamonis K, 2004. Different response of Helicobacter pylori negative and positive patients to the treatment of non ulcer dyspepsia with astaxanthin rich algal meal: a randomized double blind placebo controlled study. Abstract no 11.32. European Helicobacter Study Group. XVIIth International Workshop, Vienna, Austria, September 22–24, 2004, 1 pp.
39. Kupcinskas L, Lafolie P, Lignell A, Kiudelis G, Jonaitis L, Adamonis K, Andersen LP and Wadstrom T, 2008. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine, 15, 391–399.
40. Lignell A, Surace R, Böttiger P and Borody TJ, 1999. Symptom improvement in Helicobacter pyloripositive non-ulcer dyspeptic patients after treatment with the carotenoid astaxanthin. Abstract no 4A-3. 12th international carotenoid symposium, Cairns, Australia, July 18–23, 1999, 1 pp.
41. Lignell A, 2001, unpublished. US Pat no 6,245,818, June 12, 2001. Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases. PCT No PCT/SE98/01526. PCT Pub No WO99/11251. PCT filed Aug 26, 1998. 14 pp.
42. Liu C, Wang XD, Bronson RT, Smith DE, Krinsky NI and Russell RM, 2000. Effects of physiological versus pharmacological beta-carotene supplementation on cell proliferation and histopathological changes in the lungs of cigarette smoke-exposed ferrets. Carcinogenesis, 21, 2245–2253.
43. Liu C, Russell RM and Wang XD, 2003. Exposing ferrets to cigarette smoke and a pharmacological dose of beta-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. Journal of Nutrition, 133, 173–179.
44. Liu C, Wang XD, Mucci L, Gaziano JM and Zhang SM, 2009. Modulation of lung molecular biomarkers by beta-carotene in the Physicians' Health Study. Cancer, 115, 1049–1058.
45. Männistö S, Ovaskainen M-L and Valsta L, 2003. Finravinto 2002 - Tutkimus. The national Findiet 2002 study. Publications of the National Public Health Institute B3/2003. Helsinki, Finland, 130 pp.
46. Martin HD, Ruck C, Schmidt M, Sell S, Beutner S, Mayer B and Walsh R, 1999. Chemistry of carotenoid oxidation and free radical reactions. Pure and Applied Chemistry, 71, 2253–2262.
47. Mayne ST, Handelman GJ and Beecher G, 1996. Beta-Carotene and lung cancer promotion in heavy smokers-a plausible relationship? Journal of the National Cancer Institute, 88, 1513–1515.
48. Mercke Odeberg J, Lignell A, Pettersson A and Hoglund P, 2003. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. European Journal of Pharmaceutical Sciences, 19, 299–304.
49. Miyawaki H, Takahashi J, Tsukahara H and Takehara I, 2008. Effects of astaxanthin on human blood rheology. Journal of Clinical Biochemistry and Nutrition, 43, 69–74.
50. Nagaki Y, Mihara M, Takahashi J, Kitamura A, Horita Y, Sugiura Y and Tsukahara H, 2005. The effect of astaxanthin on retinal capillary blood flow in normal volunteers. Journal of Clinical Therapeutics & Medicine, 21, 537–542.
51. Nagata A, Tajima T and Takahashi J, 2006. Effect of astaxanthin 5 mg on anti-fatigue and task-performance of human. Carotenoid Science, 10, 102–106.
52. Nie X-P, Zie J, Häubner N, Tallmark B and Snoeijs P, 2011. Why Baltic herring and sprat are weak conduits for astaxanthin from zooplankton to piscivorous fish. Limnology and Oceanography, 56, 1155–1167.
53. Nitta T, Ohgami K, Shiratori K, Shinmai Y, Chin S, Yoshida K, Tsukuhara H and Ohno S, 2005. Effects of astaxanthin on accommodation and asthenopia – dose finding study in healthy volunteers. Journal of Clinical Therapeutics and Medicine, 21, 637–650.
54. OECD (Organisation for Economic Cooperation and Development), 1997a. Test No. 474: Mammalian Erythrocyte Micronucleus Test. In: OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. 10 pp.
55. OECD (Organisation for Economic Cooperation and Development), 1997b. Test No. 476: In vitro Mammalian Cell Gene Mutation Test. In: OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. 10 pp.
56. OECD (Organisation for Economic Cooperation and Development), 1997c. Test No. 471: Bacterial Reverse Mutation Test. In: OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. 11 pp.
57. OECD (Organisation for Economic Cooperation and Development), 2008. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. In: OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. 13 pp.
58. Ohno M, Darwish WS, Ikenaka Y, Miki W and Ishizuka M, 2011. Astaxanthin can alter CYP1A-dependent activities via two different mechanisms: induction of protein expression and inhibition of NADPH P450 reductase dependent electron transfer. Food and Chemical Toxicology, 49, 1285–1291.
59. Okada Y, Ishikura M and Maoka T, 2009. Bioavailability of astaxanthin in Haematococcus algal extract: the effects of timing of diet and smoking habits. Bioscience, Biotechnology, and Biochemistry, 73, 1928–1932.
60. Olson JA, 1989. Biological actions of carotenoids. Journal of Nutrition, 119, 94–95.
61. Osterlie M, Bjerkeng B and Liaaen-Jensen S, 2000. Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. Journal of Nutritional Biochemistry, 11, 482–490.
62. Paetau I, Chen H, Goh NM and White WS, 1997. Interactions in the postprandial appearance of beta-carotene and canthaxanthin in plasma triacylglycerol-rich lipoproteins in humans. American Journal of Clinical Nutrition, 66, 1133–1143.
63. Petri D and Lundebye AK, 2007. Tissue distribution of astaxanthin in rats following exposure to graded levels in the feed. Comparative Biochemistry and Physiology. Toxicology and Pharmacology, 145, 202–209.
64. Russell RM, 2004. The enigma of beta-carotene in carcinogenesis: what can be learned from animal studies. Journal of Nutrition, 134, 262S–268S.
65. Sakurai T, Hashizume K, Ohta M, Koike Y, Shirai M, Tomizawa A, Takahashi M, Tanaka Y and Takebuchi Y, 2002, unpublished. A single oral dose toxicity study of Astaxanthin in rats. Nippon Experimental Medical Research Institute Co., Ltd., Gunma, Japan, 33 pp.
66. Sarwar G, Inoue H and Kasumi M, 2002, unpublished. Bacterial reverse mutation test of Astaxanthin. Report H-02091. Nippon Experimental Medical Research Institute Co., Ltd., Gunma, Japan, 24 pp.
67. Satoh A, Tsuji S, Okada Y, Murakami N, Urami M, Nakagawa K, Ishikura M, Katagiri M, Koga Y and Shirasawa T, 2009. Preliminary Clinical Evaluation of Toxicity and Efficacy of A New Astaxanthin-rich Haematococcus pluvialis Extract. Journal of Clinical Biochemistry and Nutrition, 44, 280–284.
68. Sawaki K, Yoshigi H, Aoki K, Koikawa N, Azumane A, Kaneko K and Yamaguchi M, 2002. Sports performance benefits from taking natural astaxanthin characterized by visual acuity and muscular fatigue improvement in humans. Journal of Clinical Therapeutics and Medicine, 18, 73–88.
69. SCF (Scientific Committee on Food), 2002. Opinion of the Scientific Committee on Food on the risks to human health of polycyclic aromatic hydrocarbons in food. Document SCF/CS/CNTM/PAH/29 ADD1 Final, 84 pp.
70. Shimada Y, 2003, unpublished. Safety study of astaxanthin consumption in humans. Fuji Chemical Industry Co., Ltd. Internal Bulletin, Toyama, Japan, 6 pp.
71. Shiratori K, Ohgami K, Nitta T, Shinmai Y, Chin S, Yoshida K, Tsukuhara H, Isao T and Ohno S, 2005. Effect of astaxanthin on accomodation and asthenopia. Efficacy identification study in healthy volunteers. Journal of Clinical Therapeutics and Medicines, 21, 637–650.
72. Spiller GA and Dewell A, 2003. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. Journal of Medicinal Food, 6, 51–56.
73. Steinbrenner J and Linden H, 2001. Regulation of two carotenoid biosynthesis genes coding for phytoene synthase and carotenoid hydroxylase during stress-induced astaxanthin formation in the green alga Haematococcus pluvialis. Plant Physiology, 125, 810–817.
74. Stewart J, Glaister J, Henderson P, Riches S and Everett D, 2001, unpublished. HPP: 13 Week oral (dietary administration) toxicity study in the rat. Covance Report 1840/002-D6154. Covance Laboratories Ltd, Harrogate, North Yorkshire, England, 281 pp.
75. Stewart JS, Lignell A, Pettersson A, Elfving E and Soni MG, 2008. Safety assessment of astaxanthin-rich microalgae biomass: Acute and subchronic toxicity studies in rats. Food and Chemical Toxicology, 46, 3030–3036.
76. Takahashi J, Tsukahara H and Minato S, 2004. Toxicological studies of astaxanthin from Haematococcus pluvialis - Ames test, oral singl dose and 90-days subchronic toxicity studies in rats. Journal of Clinical Therapeutics and Medicines, 20, 867–888.
77. UK ACNFP (Advisory Committee on Novel Foods and Processes), 2004. Request for an article 5 opinion on the substantial equivalence of astaxanthin-rich carotenoid oleoresin extracted from Haematococcus pluvialis. US Nutra. 4 pp.
78. UK ACNFP (Advisory Committee on Novel Foods and Processes), 2007. Opinion on substantial equivalence of astaxanthin-rich oleoresin extracted from Haematococcus pluvialis considered under article 5 of the novel foods regulation. Cyanotech Corporation. 7 pp.
79. UK ACNFP (Advisory Committee on Novel Foods and Processes), 2008. Opinion on substantial equivalence of astaxanthin-rich oleoresin extracted from Haematococcus pluvialis algae considered under article 5 of the novel foods regulation. Algatechnologies (1998) Ltd. 7 pp.
80. van den Berg H, 1999. Carotenoid interactions. Nutrition Reviews, 57, 1–10.
81. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI and Russell M, 1999. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. Journal of the National Cancer Institute, 91, 60–66.
82. White WS, Stacewicz-Sapuntzakis M, Erdman JW, Jr. and Bowen PE, 1994. Pharmacokinetics of beta-carotene and canthaxanthin after ingestion of individual and combined doses by human subjects. Journal of the American College of Nutrition, 13, 665–671.
83. WHO (World Health Organization), 1998. Guidelines for Drinking Water Quality, 2nd ed. Addendum to Vol 2, Health Criteria and Other Supporting Information. Geneva, Swizerland, 127 pp.
84. Wolz E, Liechti H, Notter B, Oesterhelt G and Kistler A, 1999. Characterization of metabolites of astaxanthin in primary cultures of rat hepatocytes. Drug Metabolism and Disposition, 27, 456–462.
85. Wright ME, Groshong SD, Husgafvel-Pursiainen K, Genova E, Lucia MS, Wolff H, Virtamo J and Albanes D, 2010. Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. Cancer Prevention Research (Phila), 3, 745–752.
86. Yoshihiko K, Sachiko I, Aki S, Yoko I, Takayuki IK, Yoshihiko K, Kumiko K and Fumio M, 2004, unpublished. Subchronic 90-day toxicity study of AstaREAL oil 50F in rats. FBM 03-2165. Fuji Biomedix Co, Ltd., Kobuchisawa Research Laboratories, Yamanashi, Japan, 23 pp.
87. Yu P, 1996, unpublished. 14-day toxicity study in Sprague Dawley crl: CD (SD) BR rats treated with the test article Haematococcus pluvialis, unicellular green algae administrated by oral route at the doses of 0 and 6 g/kg/day. RBM report 950501. Instituto di Recerche Biomediche “Antoine Marxer” (RBM), Colleretto Giacosa, Torino, Italy, 31 pp.
88. Zaripheh S and Erdman JW, Jr., 2002. Factors that influence the bioavailablity of xanthophylls. Journal of Nutrition, 132, 531S–534S.